1-6 of 6
Zixun Yan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Lingshuang Sheng, Zixun Yan, Li Wang, Wen Wu, Yilun Zhang, Rong Shen, Weiguo Cao, Lei Li, Sheng Chen, Xufeng Jiang, Hongmei Yi, Qi Song, Li Wang, Shu Cheng, Pengpeng Xu, Xuanming Yang, Yuxiang Zhu, Xikang Xu, Fuzhe Wang, Jianyong Li, Wei Li Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 4822.
https://doi.org/10.1182/blood-2024-198296
Published: 2024
Journal Articles

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen, Li Wang, Pengpeng Xu, Shu Cheng, Wei Tang, Wen Wu, Mengmeng Ji, Zhong Zheng, Zixun Yan, Lingshuang Sheng, Yige Shen, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 6553.
https://doi.org/10.1182/blood-2024-203842
Published: 2024
Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Wenbin Qian, Ying Lu, Yuhua Li, Dongmei Ji, Xiaojian Zhu, Heng Mei, Ping Li, Changju Qu, Lei Zhang, Keshu Zhou, Hongmei Jing, Ting Niu, Chunyan Ji, Lanfang Li, Hua Yang, Fei Li, Wei Wang, Kailin Xu, Jinghua Zhao, Depei Wu, Yu Hu, Weili Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 5115.
https://doi.org/10.1182/blood-2024-207186
Published: 2024
Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Yuhua Li, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang Li, Fei Li, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Weili Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 6928.
https://doi.org/10.1182/blood-2023-181351
Published: 2023
Journal Articles

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Mingci Cai, MD, Shu Cheng, MD PhD, Wang Xin, PhD, Jianda Hu, PhD, Yongping Song, Zixun Yan, Yujie Jiang, MD, Xiaosheng Fang, PhD, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, MD PhD, Pengpeng Xu, Weili Zhao
Journal: Blood
Blood (2019) 134 (Supplement_1): 1556.
https://doi.org/10.1182/blood-2019-122369
Published: 2019
Journal Articles

Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Zixun Yan, Wen Wang, MD, Zhong Zheng, Ming Hao, Su Yang, James Li, Shu Cheng, Li Wang, Wei-li Zhao
Journal: Blood
Blood (2018) 132 (Supplement 1): 4187.
https://doi.org/10.1182/blood-2018-99-115769
Published: 2018